预约演示
更新于：2026-02-27
Methylprednisolone aceponate
醋丙甲泼尼龙
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H36O7 |
InChIKeyDALKLAYLIPSCQL-YPYQNWSCSA-N |
CAS号86401-95-8 |
关联
14
项与 醋丙甲泼尼龙 相关的临床试验CTR20242781
醋丙甲泼尼龙乳膏生物等效性研究与人体药代动力学对比研究。
CTIS2024-511390-30-00
Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Cream (Test) vs. Advantan(R) 0.1% Cream (Reference) vs. Vehicle in patients with mild to moderate atopic dermatitis
CTR20192503
0.1%MPA乳膏治疗湿疹有效性和安全性多中心、随机、双盲、阳性药平行对照临床研究
100 项与 醋丙甲泼尼龙 相关的临床结果
登录后查看更多信息
100 项与 醋丙甲泼尼龙 相关的转化医学
登录后查看更多信息
100 项与 醋丙甲泼尼龙 相关的专利（医药）
登录后查看更多信息
185
项与 醋丙甲泼尼龙 相关的文献（医药）2026-02-01JOURNAL OF INVESTIGATIVE DERMATOLOGY
Effect of Systemic Therapies on Skin Bacteriome in Patients with Atopic Dermatitis: A Pilot Prospective Study
Article
作者: Borilova Linhartova, Petra ; Bohm, Jan ; Jedlickova, Hana ; Ruzicka, Filip ; Thomova, Terezia ; Holochova, Pavla
Atopic dermatitis is a complex disease that requires treatments addressing skin barrier disruption, inflammation, and microbial imbalance. In this study, we aimed to investigate the effects of 4 different therapies on clinical outcomes and skin bacteriome in patients with atopic dermatitis, namely: Jak inhibitors, dupilumab, cyclosporine A, and topical corticosteroids (intermittently used methylprednisolone aceponate). Samples from 60 patients were collected before treatment and after 3 and 6 months, and their bacteriome diversity and composition were analyzed. All treatment groups showed significant improvement in disease severity after 3 months; however, only dupilumab resulted in a marked reduction in serum IgE levels and an almost complete depletion of Staphylococcus aureus. The relative abundance of this bacterium correlated with disease severity and remained significantly lower in patients receiving dupilumab than in those treated with cyclosporine A or topical corticosteroids. Although overall bacteriome alpha diversity remained unchanged, the ratio of Staphylococcus to Corynebacterium and Cutibacterium decreased significantly after Jak inhibitors as well as dupilumab treatment but remained stable with cyclosporine A and topical corticosteroids. These results indicate that addressing type 2 inflammation by targeted drugs alters the skin bacteriome toward a healthy balance, whereas traditional anti-inflammatory treatments have minimal impact on microbial composition.
2026-01-01Gastro hep advances
Increasing Social Vulnerability Impacts Presentation and Decreases Treatment Response in Eosinophilic Esophagitis
Article
作者: Redd, Walker D ; Gee, Timothy S ; Bermudez, Jose C ; Lackey, Angelica R ; LaFata, Sean S ; Lee, Christopher J ; Weir, Alexandra A ; Juneja, Arjun K ; Thel, Hannah L ; Aleman, Stefani ; Barlowe, Trevor S ; McCallen, Justin ; Dellon, Evan S ; Cameron, Brenderia A ; Hendrick, Gustaf N ; Song, Daniel ; Reed, Craig C ; Cotton, Cary C
Background and Aims:
Social vulnerability describes relative disadvantage according to demographics, socioeconomic status, and resources. The impact of social vulnerability on eosinophilic esophagitis (EoE) remains unknown. We aimed to determine whether social vulnerability influences EoE presentation or treatment outcomes.
Methods:
We conducted a retrospective cohort study of patients of any age with newly diagnosed EoE. The social vulnerability index (SVI) was used to estimate patients' relative vulnerability (with higher scores indicating more vulnerability). For patients with topical corticosteroid (tCS) treatment or dietary elimination and a follow-up endoscopy, we assessed histologic, symptomatic, and endoscopic responses. We compared baseline characteristics and post-treatment responses by SVI.
Results:
Among 1457 patients, the mean SVI was 0.42 ± 0.26. Patients with higher SVIs frequently presented with atypical symptoms like vomiting (P < .001), abdominal pain (P = .01), or nausea (P = .01). The SVI was similar for patients treated with tCS or dietary elimination (mean 0.41 vs 0.40). However, patients with higher SVIs had decreased histologic response to tCS treatment that persisted after adjusting for confounders (adjusted odds ratio 0.32 for response <15 eosinophils per high-power field; 95% confidence interval: 0.18-0.65). When analyzing SVI by quartiles, patients in the highest quartile (highest social vulnerability) had 58% lower odds of histologic response to tCS compared to patients with the lowest social vulnerability (adjusted odds ratio 0.42, 95% confidence interval: 0.21-0.84). SVI was not associated with histologic response after dietary elimination.
Conclusion:
In patients with EoE, higher social vulnerability was independently associated with lower histologic response to tCS. This association warrants further exploration of explanatory factors, including treatment adherence and increased allostatic load.
2025-11-04Boletin Medico del Hospital Infantil de Mexico
Article
作者: Toussaint-Caire, Sonia ; Valencia-Herrera, Adriana M ; Mena-Cedillos, Carlos A ; Dávila-Patiño, Miriam ; Pérez-López, Citlalli F ; Toledo-Bahena, Mirna E ; Vega-Memije, Ma Elisa
Background:
Generalized pustular psoriasis is a rare and severe systemic inflammatory disease characterized by skin erythema and visible sterile pustules. Associated with hereditary and external factors, it can be life-threatening and requires specialized diagnosis and treatment.
Clinical case:
A 6-year-old male with disseminated dermatosis of 7 months evolution, initially appearing in the retroauricular region with erythematous scaly plaques and pustular lesions, spreading to various body segments, accompanied by intense pruritus, fever, and tachycardia. Histopathological examination reported psoriasiform dermatitis with lymphocytes, plasma cell aggregates, and neutrophils forming microabscesses in the stratum corneum, compatible with a diagnosis of pustular psoriasis. Treatment included methotrexate at 12 mg/m²/week, folic acid, 1% methylprednisolone aceponate cream, 0.005% calcipotriol, urea-based emollient at 10%, and antihistamines.
Conclusions:
Generalized pustular psoriasis in pediatrics requires comprehensive care, considering not only dermatological aspects but also psychosocial factors. Successful management of pediatric cases, as described, highlights the importance of a personalized approach tailored to each patient's needs to achieve long-term satisfactory outcomes.
7
项与 醋丙甲泼尼龙 相关的新闻（医药）2026-01-22
·三弟药闻
申请上市临床申请引进/卖出
100 项与 醋丙甲泼尼龙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 银屑病 | 澳大利亚 | 1994-07-11 | |
| 湿疹 | 瑞士 | 1991-12-19 | |
| 特应性皮炎 | 瑞士 | 1991-12-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 神经性皮炎 | 临床3期 | 中国 | 2013-10-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用